Respiratory
Bellerophon’s study of fILD therapy fails to meet primary endpoint
US-based biotechnology firm Bellerophon Therapeutics has reported that its Phase III REBUILD clinical trial of INOpulse for the treatment of…
ASCO 2023: Janssen present positive follow-up data for first in line therapy for lung cancer
Janssen Pharmaceuticals has presented long-term results from its CHRYSALIS study, which showed the combination of Rybrevant (amivantamab-vmjw) and lazertinib, was…
AstraZeneca reports positive results from ADAURA Phase III trial
AstraZeneca has reported positive results from the ADAURA Phase III trial of Tagrisso (osimertinib) in the adjuvant treatment of patients…
Stallergenes Greer initiates Phase III study of Staloral Birch
Stallergenes Greer has initiated a Phase III clinical study of Staloral Birch to treat children and adolescents with birch pollen-induced…
Cumberland to launch Phase II trial of ifetroban for IPF
Cumberland Pharmaceuticals has announced plans to launch the Phase II FIGHTING FIBROSIS trial of oral ifetroban for idiopathic pulmonary fibrosis…
Subscribe to our Newsletter
Get industry leading news, data and analysis delivered to your inbox
BMS’s LPA1 antagonist to enter Phase III IPF trial
Bristol Myers Squibb (BMS) will continue investigating BMS-986278 in a global Phase III trial program in patients with idiopathic pulmonary…
Trevi reports positive results from trial of Haduvio for chronic cough
US-based pharmaceutical company Trevi Therapeutics has reported positive results from the Phase II Cough And NALbuphine (CANAL) trial of Haduvio…
Apnimed reports OSA oral drug’s positive Phase IIb trial results
Apnimed has reported positive results from the MARIPOSA Phase IIb trial of AD109 (aroxybutynin 2.5mg/atomoxetine 75mg) for the treatment of…
Hummingbird and Merck to evaluate combination therapy for NSCLC
Singapore-based biotechnology company Hummingbird Bioscience has partnered with Merck to evaluate its HER3-targeting antibody HMBD-001 in combination with cetuximab in…
Ascletis wins NMPA approval to initiate RSV Phase IIa therapy trial
Ascletis Pharma has received approval from the China National Medical Products Administration (NMPA) to initiate a Phase IIa clinical trial…